公开(公告)号：WO2023067170A1

公开(公告)日：2023-04-27

申请号：PCT/EP2022/079438

申请日：2022-10-21

Applicant: FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA ,  FUNDACIÓN PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA ,  UNIVERSITAT DE BARCELONA

Inventor： FERNÀNDEZ BUSQUETS, Xavier ,  BIOSCA ROMANILLOS, Arnau ,  BOUZÓN ARNÁIZ, Inés ,  MUÑOZ-TORRERO LÓPEZ-IBARRA, Diego ,  MARTÍNEZ ARCE, Elsa ,  REOLID COLL, Pau

IPC: A61P33/06 ,  C07D213/38 ,  C07D401/14 ,  A61K31/4427

Abstract: Bis(aminostyrylpyridinium) compounds of formula (I) and pharmaceutical acceptable salts thereof are provided for use as a medicament. Additionally, multiple novel bis(aminostyrylpyridinium) compounds of formula (I) are provided. The present invention relates to compounds of formula (I) and compositions for use in the treatment of a disease whose etiology is based on protein aggregation. Particularly, compounds are useful in the treatment, prevention or amelioration of malaria, or symptoms, complications and/or sequelae thereof.

公开(公告)号：WO2023006954A1

公开(公告)日：2023-02-02

申请号：PCT/EP2022/071374

申请日：2022-07-29

Applicant: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) ,  UNIVERSITAT DE BARCELONA ,  UNIVERSIDAD DE BURGOS ,  NOSTRUM BIODISCOVERY, S.L.

Inventor： SOTO CERRATO, Vanessa ,  KORRODI MINEIRO MARQUES GREGÓRIO, Luis ,  MARTÍNEZ GARCÍA, David ,  PÉREZ TOMÁS, Ricardo Enrique ,  SOLIVA SOLIVA, Robert ,  GUALLAR TASIES, Victor ,  DÍAZ BUENO, Lucia ,  QUESADA PATO, Roberto ,  GARCÍA VALVERDE, María

IPC: A61K31/407 ,  A61K31/555 ,  A61K31/7068 ,  A61K33/243 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04

Abstract: It relates to a compound of formula (I), particularly asenapine, or a pharmaceutically acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically acceptable salts, for use in the treatment and/or prevention of cancer. It also relates to a drug combination of a compound of formula (I), its stereoisomers and/or salts thereof, and one or more anticancer agents selected from the group consisting of chemotherapy agents, immunotherapy agents, and hormone therapy agents; and to pharmaceutical compositions and to a kit of parts comprising this combination, as well as the use of the drug combination, the compositions, or kit of parts for use in the treatment and/or prevention of cancer.

公开(公告)号：WO2022229490A1

公开(公告)日：2022-11-03

申请号：PCT/ES2022/070265

申请日：2022-04-29

Applicant: DEPURACIÓN DE AGUAS DEL MEDITERRÁNEO, S.L. ,  FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (IBEC) ,  UNIVERSITAT DE BARCELONA

Inventor： DOÑATE HERNÁNDEZ, Silvia ,  ESCLAPEZ VICENTE, María Deseada ,  BURGUÉS CALDERÓN, Javier ,  MARCO COLÁS, Santiago ,  SAÚCO BOZIC, Lidia Clara

IPC: G01N1/22

Abstract: La presente invención es un dron para la medición de concentración de olor caracterizado por una configuración específica que permite la toma de muestras en localizaciones que de otra forma tendrían difícil acceso o no serían accesibles y, en unas condiciones en las que los medios de impulsión no afectan a la medida. Adicionalmente, la invención está caracterizada por el correcto marcado de la localización espacial de cada toma de muestra y medida aunque la toma de muestra y medida requiera un tiempo de transporte del aire aspirado.

公开(公告)号：WO2022147304A1

公开(公告)日：2022-07-07

申请号：PCT/US2021/065757

申请日：2021-12-30

Applicant: ARCTURUS THERAPEUTICS, INC. ,  CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, M.P. ,  INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE GIRONA DR JOSEP TRUETA ,  UNIVERSITAT DE BARCELONA

Inventor： TRELLES, Ramón Díaz ,  TACHIKAWA, Kiyoshi ,  KARMALI, Priya Prakash ,  MUKTHAVARAM, Rajesh ,  CHIVUKULA, Padmanabh ,  MORENO-NAVARRETE, José María ,  NAVARRO, Aleix Gavaldà ,  FERNÁNDEZ-REAL, José Manuel ,  OMS, Marta Giralt ,  GOMBAU, Francesc Villarroya

IPC: A61K31/7125 ,  A61K31/713 ,  C12N15/11 ,  C12N15/113

Abstract: Provided herein are compositions and methods for treating metabolic disorders, such as hepatic steatosis, adipose tissue dysfunction, and insulin resistance. Small interfering RNAs (siRNAs) targeting LPS -binding protein (LBP) that include unlocked nucleotides (UNA) and their therapeutic applications for the treatment of metabolic disorders are provided herein.

公开(公告)号：WO2021064165A1

公开(公告)日：2021-04-08

申请号：PCT/EP2020/077642

申请日：2020-10-02

Applicant: UNIVERSITAT DE BARCELONA ,  UNIVERSITAT POMPEU FABRA ,  UNIVERSITAT AUTÒNOMA DE BARCELONA ,  INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES ,  FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA

Inventor： CASADÓ BURILLO, Vicent ,  MORENO GUILLÉN, Estefania ,  MALDONADO LÓPEZ, Rafael ,  ANDREU MARTÍNEZ, David ,  GALLO, María ,  PARDO CARRASCO, Leonardo ,  CASTANHO, Miguel ,  NEVES, Vera ,  CAVACO, Marco

IPC: C07K7/08 ,  A61P25/00 ,  A61K38/00

Abstract: The present invention relates to compounds of formula (I): AA1-AA2-D-Ile-AA3-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.

公开(公告)号：WO2020212297A1

公开(公告)日：2020-10-22

申请号：PCT/EP2020/060370

申请日：2020-04-14

Applicant: INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS) ,  FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA ,  HOSPITAL CLÍNIC DE BARCELONA ,  UNIVERSITAT DE BARCELONA

Inventor： SUÑÉ NEGRE, Josep M. ,  SORIANO VILADOMIU, Alex ,  AIRA GOMEZ, Andrea ,  FEHER, Csaba

IPC: A61K9/48 ,  A61K35/74 ,  A61K35/741

Abstract: The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

公开(公告)号：WO2020193448A1

公开(公告)日：2020-10-01

申请号：PCT/EP2020/057914

申请日：2020-03-23

Applicant: UNIVERSITAT DE BARCELONA

Inventor： MUÑOZ-TORRERO LÓPEZ-IBARRA, Diego ,  VÁZQUEZ CRUZ, Santiago ,  PONT MASANET, Caterina ,  CODONY GISBERT, Sandra

IPC: A61K31/4706 ,  A61P25/28 ,  C07D215/46 ,  C07D401/12

Abstract: The invention provides compounds of formula I wherein: m is 0, 1 or 2; n is 2, 3, 4 or 5; R 0 and R 1 are both H, or they form a bridge -CH 2 -C(R 4 )=CH-, R 4 being CH 3 or CH 2 CH 3 ; R 2 and R 3 independently are H, F, Cl or (C 1 -C 4 )-alkyl; R 5 is H, F, Cl, Br, I, OCH 3 , OCF 3 , SF 5 , SO 2 F, SO 2 CH 3 , NO 2 , CF 3 or (C 1 -C 4 )-alkyl; R 6 and R 7 independently are H, F, Cl, CH 3 or CF 3 ; and optionally R 5 and R 6 form a bridge -O-CH 2 -O-, R 7 being H, in vitro assays show that compounds I are simultaneously inhibitors of acetylcholinesterase and inhibitors of soluble epoxide hydrolase, and that they have a good blood-brain barrier permeability. Thus, compounds I are multitarget active pharmaceutical ingredients for the treatment of Alzheimer's disease in humans.

公开(公告)号：WO2020074405A1

公开(公告)日：2020-04-16

申请号：PCT/EP2019/076997

申请日：2019-10-07

Applicant: UNIVERSITAT DE BARCELONA

Inventor： RABANAL ANGLADA, Francesc

IPC: C07K7/62 ,  A61K38/12

Abstract: It relates to polymyxin analogues having a disulfide bond and an amino alcohol group adjacent to the disulfide bond, and optionally, an ester bond in the peptide backbone, which are useful as antibacterial agent, as well as to pharmaceutical compositions comprising them. It also relates to a key intermediate compound of formula (II) and its preparation process.

公开(公告)号：WO2020007761A1

公开(公告)日：2020-01-09

申请号：PCT/EP2019/067517

申请日：2019-07-01

Applicant: UNIVERSITAT DE BARCELONA

Inventor： MONTES USATEGUI, Mario ,  BOLA SAMPOL, Raúl ,  MARTÍN BADOSA, Estela ,  TREPTOW, Dorian

IPC: G02B21/00 ,  G02F1/11 ,  G02B26/10

Abstract: A programmable multiple-point illuminator for an optical microscope (M) comprises a light source (1, 2)and a spatial light modulator (SLM) to modulate a light beam from the light source. The modulated light beam is intended to scan across a sample placed under the microscope objective (21), the sample being provided with fluorophores. The SLM comprises a first acousto-optic deflector (8) and a second acousto-optic deflector (9), the first acousto-optic deflector having a first modulation plane (81) and the second acousto- optic deflector having a second modulation plane (91), said two acousto-optic deflectors being arranged in cascade to provide respective deflection in different directions, whereby the SLM is enabled to scan in two dimensions across the sample. The SLM further comprises a telescope relay (10) to conjugate the first modulation plane with the second modulation plane. The illuminator also comprises an arbitrary waveform generator (13) that is configured to synthesize holograms, and is arranged to simultaneously inject a first such hologram into the first acousto-optic deflector and a second such hologram into the second acousto-optic deflector, in order for the SLM to modulate the light beam in response to said holograms.

公开(公告)号：WO2019233887A1

公开(公告)日：2019-12-12

申请号：PCT/EP2019/064165

申请日：2019-05-31

Applicant: UNIVERSITAT DE BARCELONA

Inventor： SUÑÉ NEGRE, José María ,  MERCADÉ FRUTOS, Débora

IPC: A61K9/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/24 ,  A61K47/44 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4965

Abstract: Kit of products for extemporaneous preparation of an oily suspension formulation comprising: (i) a dry powder composition of anti-tuberculosis effective amounts of the active pharmaceutical ingredients (APIs): isoniazid, rifampicin and pyrazinamide; and (ii) an oily liquid dispersing medium for reaching a predetermined volume of the suspension formulation, comprising: adequate amounts of the dispersing agents: ethoxylated hydrogenated castor oil, simethicone, and dichlorodimethylsilane-treated silica; adequate amounts of one or more flavoring agents; and the amount of medium-chain triglycerides, as oily base, that is necessary for reaching the predetermined volume of the suspension formulation; wherein (i) and (ii) are packaged in physically separated containers, arranged to be mixed extemporaneously to form the suspension formulation.The formulation is stable for more than three weeks under fridge conditions, and it is useful as a first-line treatment of tuberculosis in humans, particularly in children, with easy dose control, little effort, and good adherence.